Efficacy and tolerability of vortioxetine versus agomelatine, categorized by previous treatment, in patients with major depressive disorder switched after an inadequate response

Autor: Marianne Dragheim, Brigitte Tonnoir, George I. Papakostas, Rebecca Z. Nielsen

Publikováno v: Journal of Psychiatric Research. 101:72-79

This study aimed to evaluate if efficacy and tolerability of switching to vortioxetine is independent of previous SSRI or SNRI treatment in patients who had been inadequately treated for their current major depressive episode. Patients from a double-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25cd056da8ec525c230c198788170a5d
https://doi.org/10.1016/j.jpsychires.2018.02.017

A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder

Autor: Marianne Dragheim, Enric Álvarez, Henrik Loft, Francesc Artigas, Víctor Pérez

Publikováno v: The International Journal of Neuropsychopharmacology
Digital.CSIC. Repositorio Institucional del CSIC
instname
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona

The efficacy, safety, and tolerability of Lu AA21004 vs. placebo using venlafaxine XR as active reference in patients with DSM-IV-TR major depressive disorder (MDD) were evaluated. Lu AA21004 is a novel antidepressant that is a 5-HT3 and 5-HT7 recept

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9986e70a226cd06f0145c4212112bc63
http://europepmc.org/articles/PMC3349292

A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD)

Autor: Henrik Loft, Marianne Dragheim, David S. Baldwin

Publikováno v: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 22(7)

The efficacy, safety, and tolerability of Lu AA21004 versus placebo, using duloxetine as active reference, in patients with DSM-IV-TR diagnosed major depressive disorder (MDD) were evaluated in this 8-week, multi-site study. Patients (n=766) had a ba

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c53766fb4ff9ed541258e42d0f11098b
https://pubmed.ncbi.nlm.nih.gov/22209361

P.2.c.024 A double-blind, randomised, placebocontrolled, relapse-prevention study with Lu AA21004 in patients with major depressive disorder

Autor: Jean-Philippe Boulenger, Marianne Dragheim, Ioana Florea, Henrik Loft

Publikováno v: European Neuropsychopharmacology. 21:S396-S397

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9e9f69f3ae17182038d28d81c673a367
https://doi.org/10.1016/s0924-977x(11)70638-1

P.2.c.040 A randomised, double-blind, placebo-controlled, active-referenced study of Lu AA21004 in patients with major depression

Autor: Francesc Artigas, Henrik Loft, Enric Álvarez, Virgili Pérez, Marianne Dragheim

Publikováno v: European Neuropsychopharmacology. 19:S426-S427

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5e266369d6ffbced0c01db823e581d53
https://doi.org/10.1016/s0924-977x(09)70661-3